推荐产品
product name
GLP-1R 激动剂, ≥98% (HPLC)
化驗
≥98% (HPLC)
形狀
powder
儲存條件
desiccated
顏色
light brown-yellow
溶解度
DMSO: ≥10 mg/mL
儲存溫度
2-8°C
InChI
1S/C13H15Cl2N3O2S/c1-13(2,3)18-11-12(21(4,19)20)17-10-6-8(15)7(14)5-9(10)16-11/h5-6H,1-4H3,(H,16,18)
InChI 密鑰
GNZCSGYHILBXLL-UHFFFAOYSA-N
一般說明
胰高血糖素样肽-1 受体 (GLP-1R) 激动剂是糖尿病患者调节胰高血糖素样肽 (GLP)-1 的潜在口服药物。GLP-1R 激动剂在降低糖化血红蛋白水平中起关键作用。改善血糖控制和维持体重。
生化／生理作用
GLP-1R 是一种小分子 GLP-1 受体激动剂。GLP-1 受体信号转导是调节葡萄糖稳态的主要机制。该化合物代表了一种独特的非肽类工具，用于研究 GLP-1 在体内和体外糖尿病和肥胖模型中的作用。
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
其他客户在看
Juliana de F Germano et al.
Scientific reports, 10(1), 8284-8284 (2020-05-20)
Given that adverse remodeling is the leading cause of heart failure and death in the USA, there is an urgent unmet need to develop new methods in dealing with this devastating disease. Here we evaluated the efficacy of a short-course
GLP-1 receptor agonists: a review of head-to-head clinical studies.
Trujillo JM, et al.
Therapeutic advances in endocrinology and metabolism, 6(1), 19-28 (2015)
Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability.
Garber AJ.
Diabetes Care, 34(Supplement 2), S279-S284 (2011)
Juliana de Freitas Germano et al.
International journal of molecular sciences, 22(16) (2021-08-28)
Cardiovascular disease is the main cause of death worldwide, making it crucial to search for new therapies to mitigate major adverse cardiac events (MACEs) after a cardiac ischemic episode. Drugs in the class of the glucagon-like peptide-1 receptor agonists (GLP1Ra)
Small-molecule agonists for the glucagon-like peptide 1 receptor.
Knudsen LB, et al.
Proceedings of the National Academy of Sciences of the USA, 104(3), 937-942 (2007)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门